Oculis (NASDAQ:OCS) Hits New 12-Month High – Should You Buy?

Shares of Oculis Holding AG (NASDAQ:OCS) reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $26.89 and last traded at $26.04, with a volume of 384101 shares changing hands. The stock had previously closed at $26.00.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Needham & Company LLC restated a “buy” rating and issued a $36.00 price target on shares of Oculis in a report on Tuesday, November 11th. Stifel Nicolaus boosted their target price on Oculis from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Wall Street Zen upgraded Oculis from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a research note on Wednesday, October 8th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Oculis in a research note on Friday, December 19th. They issued an “overweight” rating and a $38.00 price objective on the stock. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $41.50.

Oculis Stock Up 0.2%

The company has a market cap of $1.36 billion, a PE ratio of -10.33 and a beta of 0.31. The firm has a 50-day simple moving average of $20.75 and a two-hundred day simple moving average of $19.27. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.47 and a quick ratio of 4.47.

Oculis (NASDAQ:OCS) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.10. The business had revenue of $0.31 million for the quarter, compared to the consensus estimate of $0.23 million. Oculis had a negative return on equity of 80.82% and a negative net margin of 12,915.42%. Research analysts anticipate that Oculis Holding AG will post -2.09 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Oculis

Several hedge funds have recently modified their holdings of OCS. Aventura Private Wealth LLC purchased a new position in shares of Oculis during the fourth quarter valued at approximately $80,000. Bosun Asset Management LLC purchased a new stake in Oculis in the 2nd quarter worth approximately $378,000. Marshall Wace LLP acquired a new position in Oculis in the 2nd quarter valued at $393,000. Geode Capital Management LLC raised its holdings in Oculis by 27.7% in the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after acquiring an additional 6,384 shares during the last quarter. Finally, Bank of America Corp DE lifted its stake in shares of Oculis by 2.2% during the 2nd quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after purchasing an additional 878 shares during the period. 22.30% of the stock is owned by institutional investors and hedge funds.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.